$BPTH
BIO-PATH HOLDINGS, INC.

2017 Q1 Form 10-K Financial Statement

#000114420417014602 Filed on March 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q2
Revenue $0.00 $13.00K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $970.0K $730.0K $760.0K
YoY Change 14.12% 23.73% 33.33%
% of Gross Profit
Research & Development $1.026M $950.0K $1.190M
YoY Change 0.59% 9.2% 110.99%
% of Gross Profit
Depreciation & Amortization $33.00K $50.00K $50.00K
YoY Change 230.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.996M $1.681M $1.944M
YoY Change 6.8% 14.9% 71.88%
Operating Profit -$1.996M -$1.668M
YoY Change 6.8% 14.01%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $1.599M $297.0K $2.000K
YoY Change 79850.0% 5840.0% -60.0%
Pretax Income -$400.0K -$1.370M -$1.940M
YoY Change -78.61% -6.16% 71.68%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$397.0K -$1.371M -$1.942M
YoY Change -78.74% -5.97% 72.47%
Net Earnings / Revenue -10546.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$833.3K -$2.854M -$4.311M
COMMON SHARES
Basic Shares Outstanding 95.65M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.110M $9.380M $4.220M
YoY Change 9.89% 5.99% -61.91%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.240M $902.0K $1.860M
YoY Change -8.82% 403.91% 95.79%
Inventory
Prepaid Expenses $376.0K
Receivables
Other Receivables
Total Short-Term Assets $8.350M $10.65M $6.080M
YoY Change 6.64% 11.05% -49.46%
LONG-TERM ASSETS
Property, Plant & Equipment $872.0K $614.0K $51.00K
YoY Change 1306.45% 752.78% -44.9%
Goodwill
YoY Change
Intangibles $889.0K $929.0K $1.010M
YoY Change -15.33% -14.77% -13.72%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.760M $1.543M $1.060M
YoY Change 57.71% 32.79% -16.05%
TOTAL ASSETS
Total Short-Term Assets $8.350M $10.65M $6.080M
Total Long-Term Assets $1.760M $1.543M $1.060M
Total Assets $10.11M $12.20M $7.140M
YoY Change 13.01% 13.4% -46.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $90.00K $69.00K $120.0K
YoY Change -55.22% 27.78% -68.84%
Accrued Expenses $610.0K $969.0K $690.0K
YoY Change -12.73% 9.74% 122.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $710.0K $1.050M $813.0K
YoY Change -21.11% 12.06% 17.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.310M $2.910M
YoY Change
Total Long-Term Liabilities $1.310M $2.910M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $710.0K $1.050M $813.0K
Total Long-Term Liabilities $1.310M $2.910M $0.00
Total Liabilities $2.020M $3.956M $813.0K
YoY Change 124.44% 322.2% 17.83%
SHAREHOLDERS EQUITY
Retained Earnings -$32.13M -$29.19M
YoY Change 26.59% 30.22%
Common Stock $96.00K $90.00K
YoY Change 6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.090M $8.240M $6.327M
YoY Change
Total Liabilities & Shareholders Equity $10.11M $12.20M $7.140M
YoY Change 12.96% 13.4% -46.28%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$397.0K -$1.371M -$1.942M
YoY Change -78.74% -5.97% 72.47%
Depreciation, Depletion And Amortization $33.00K $50.00K $50.00K
YoY Change 230.0% 0.0% 0.0%
Cash From Operating Activities -$1.840M -$1.610M -$2.250M
YoY Change -22.69% 61.0% 64.23%
INVESTING ACTIVITIES
Capital Expenditures $424.0K -$310.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$424.0K -$310.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -$1.840M -1.610M -2.250M
Cash From Investing Activities -$424.0K -310.0K
Cash From Financing Activities 0.000
Net Change In Cash -$2.264M -1.920M -2.250M
YoY Change -4.87% 92.0% 64.23%
FREE CASH FLOW
Cash From Operating Activities -$1.840M -$1.610M -$2.250M
Capital Expenditures $424.0K -$310.0K
Free Cash Flow -$2.264M -$1.300M
YoY Change 30.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 us-gaap Revenues
Revenues
0 USD
CY2016 us-gaap Revenues
Revenues
13000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1630000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5474000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2715000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3014000 USD
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1725000 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
4542000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
8488000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-4542000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-8475000 USD
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-146000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
161000 USD
CY2016 us-gaap Adjustment For Amortization
AdjustmentForAmortization
161000 USD
CY2014 us-gaap Depreciation
Depreciation
10000 USD
CY2016 us-gaap Depreciation
Depreciation
43000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-4519000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-6750000 USD
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89282000 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92704000 shares
CY2015 us-gaap Revenues
Revenues
0 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3020000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2465000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
5485000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-5467000 USD
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89763000 shares
CY2015 us-gaap Adjustment For Amortization
AdjustmentForAmortization
161000 USD
CY2015 us-gaap Depreciation
Depreciation
41000 USD
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
405000 USD
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
79000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
375000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5005000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-5005000 USD
CY2014Q4 us-gaap Cash
Cash
13859000 USD
CY2015Q4 us-gaap Cash
Cash
8854000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
104000 USD
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-184000 USD
CY2016 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
723000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
267000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3817000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8148000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14247000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9007000 USD
CY2014 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
10307000 USD
CY2016 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
521000 USD
CY2013Q4 us-gaap Cash
Cash
3552000 USD
CY2016Q4 us-gaap Cash
Cash
9375000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
338000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-123000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-338000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435000 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13800000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2015Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1100000 USD
CY2015Q4 us-gaap Other Finite Lived Intangible Assets Gross
OtherFiniteLivedIntangibleAssetsGross
2500000 USD
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5441673 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5078611 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4734861 shares
CY2015Q4 us-gaap Other Inventory
OtherInventory
600000 USD
CY2016Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
100000 USD
CY2014Q1 bpth Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
15000000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.09
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.33
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.51
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.38 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0212 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.09 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
114 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
116 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
61 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
291 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
27000000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
77000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9166000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6641000 USD
CY2015Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
64000 USD
CY2016Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
60000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
877000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1259000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
293000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
443000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7964000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10969000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7964000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10965000 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4000 USD
CY2015Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
22000 USD
CY2016Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
32000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-10000 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9000 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1859000 USD
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1550000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2295000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5467000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4560000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6750000 USD
CY2015 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
89000 USD
CY2014 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
83000 USD
CY2016 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
117000 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
132000 USD
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
132000 USD
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
252000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1899000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1530000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3001000 USD
CY2015 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0 USD
CY2014 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
21000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
3000 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
48000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
5000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q1 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
1379000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1131000 USD
CY2015Q3 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Revenues
Revenues
0 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1512000 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
1463000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1379000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1131000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1512000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1463000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 USD
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1375000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1126000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1508000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-1458000 USD
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
1869000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
1944000 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
CY2016Q4 us-gaap Revenues
Revenues
13000 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
1681000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2994000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1668000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1424000 USD
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
297000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1867000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1942000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1570000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1371000 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016 dei Trading Symbol
TradingSymbol
BPTH
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95645224 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
376000 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
560000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
902000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
179000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
10653000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
9593000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
708000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
94000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51000 USD
CY2016Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500000 USD
CY2015Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1571000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1410000 USD
CY2016Q4 us-gaap Assets
Assets
12196000 USD
CY2015Q4 us-gaap Assets
Assets
10755000 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
929000 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1090000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
614000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
69000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
54000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
969000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
883000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4783000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1050000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
937000 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2906000 USD
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Liabilities
Liabilities
3956000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
937000 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
96000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
90000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40278000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35112000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32134000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25384000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
8240000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
9818000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12196000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10755000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5882352 shares
CY2016Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9300000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95645224 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95645224 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1713000 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
784000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
369000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
404000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13813000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
436000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
404000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
14917000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
368000 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4388000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
784000 USD
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Concentration of Credit Risk &#151;</font></i></b> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. As a result, as of December 31, 2016, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.1</font> million of our cash balances was not covered by the FDIC. As of December 31, 2015 we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.9</font> million in cash on-hand, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.6</font> million was not covered by the FDIC.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Use of Estimates &#151;</font></i></b> <font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company&#8217;s estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
4600000 USD
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2900000 USD
CY2016 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
1700000 USD
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2906000 USD
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4619000 USD
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1713000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016Q4 bpth Accrued Laboratory Expense
AccruedLaboratoryExpense
200000 USD
CY2016Q4 bpth Accrued Clinical And Preclinical
AccruedClinicalAndPreclinical
200000 USD
CY2016Q4 bpth Accrued License Maintenance Fee
AccruedLicenseMaintenanceFee
100000 USD
CY2016 bpth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9007000 USD
CY2015 bpth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
6000 USD
CY2015 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
0 USD
CY2014 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
0 USD
CY2016 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
582000 USD
CY2015 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
0 USD
CY2014 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
0 USD
CY2016 bpth Research And Development Tax Credit Carryforward Expiration Period
ResearchAndDevelopmentTaxCreditCarryforwardExpirationPeriod
P2028Y
CY2016Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
48000 USD
CY2016 us-gaap General Discussion Of Pension And Other Postretirement Benefits
GeneralDiscussionOfPensionAndOtherPostretirementBenefits
We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of each employees base salary up to the allowable amount which is fully vested on the date the matching contributions are made.
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2016 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
100000 USD
CY2016Q4 bpth Drug Supplier Commitments Development
DrugSupplierCommitmentsDevelopment
200000 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5951000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y7M6D
CY2016 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Option Outstanding Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionOutstandingWeightedAverageExercisePricePerShare
3.43
CY2016Q4 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableNumberOfShares
2760000 shares
CY2016 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePricePerShare
4.73
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000 USD
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2000000 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 USD
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y10M24D
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016Q2 dei Entity Public Float
EntityPublicFloat
163300000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2016Q4 us-gaap Other Commitment
OtherCommitment
500000 USD
CY2016Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000 USD
CY2014 bpth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13812000 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
247000 USD
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2015Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000 USD
CY2015Q4 bpth Accrued Clinical And Preclinical
AccruedClinicalAndPreclinical
300000 USD
CY2015Q4 bpth Accrued License Maintenance Fee
AccruedLicenseMaintenanceFee
100000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000 USD

Files In Submission

Name View Source Status
0001144204-17-014602-index-headers.html Edgar Link pending
0001144204-17-014602-index.html Edgar Link pending
0001144204-17-014602.txt Edgar Link pending
0001144204-17-014602-xbrl.zip Edgar Link pending
bpth-20161231.xml Edgar Link completed
bpth-20161231.xsd Edgar Link pending
bpth-20161231_cal.xml Edgar Link unprocessable
bpth-20161231_def.xml Edgar Link unprocessable
bpth-20161231_lab.xml Edgar Link unprocessable
bpth-20161231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg10img1_10k.jpg Edgar Link pending
pg11img1_10k.jpg Edgar Link pending
pg11img2_10k.jpg Edgar Link pending
pg12img1_10k.jpg Edgar Link pending
pg12img2_10k.jpg Edgar Link pending
pg13img1_10k.jpg Edgar Link pending
pg14img1_10k.jpg Edgar Link pending
pg15img1_10k.jpg Edgar Link pending
pg16img1_10k.jpg Edgar Link pending
pg16img2_10k.jpg Edgar Link pending
pg43img1_10k.jpg Edgar Link pending
pg4img1_10k.jpg Edgar Link pending
pg5img1_10k.jpg Edgar Link pending
pg78img1_10k.jpg Edgar Link pending
pg9img1_10k.jpg Edgar Link pending
pg9img2_10k.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v461046_10k.htm Edgar Link pending
v461046_ex21-1.htm Edgar Link pending
v461046_ex23-1.htm Edgar Link pending
v461046_ex23-2.htm Edgar Link pending
v461046_ex31.htm Edgar Link pending
v461046_ex32.htm Edgar Link pending